Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,166,814 papers from all fields of science
Search
Sign In
Create Free Account
L 084
Known as:
L-084
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Carbapenems
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Extensively drug-resistant Pseudomonas aeruginosa ventriculitis and meningitis treated with intrathecal colistin.
G. Karagoz
,
A. Kadanalı
,
+4 authors
S. Naderi
International Journal of Antimicrobial Agents
2014
Corpus ID: 205171352
2006
2006
Syntheses and Pharmacokinetic Studies of Prodrug Esters for the Development of Oral Carbapenem, L-084
T. Isoda
,
Hideki Ushirogochi
,
+9 authors
Y. Nagao
Journal of antibiotics (Tokyo. )
2006
Corpus ID: 9156754
We discovered an orally active carbapenem, L-084, through pharmacokinetic studies on various prodrug esters of (1R,5S,6S)-6-[(R…
Expand
2006
2006
A practical and facile synthesis of azetidine derivatives for oral carbapenem, L-084.
T. Isoda
,
I. Yamamura
,
S. Tamai
,
T. Kumagai
,
Y. Nagao
Chemical and pharmaceutical bulletin
2006
Corpus ID: 24792329
An orally active carbapenem L-084, which exhibits high bioavailability in humans, has a 1-(1,3-thiazolin-2-yl)azetidin-3-ylthio…
Expand
2005
2005
L-084 子どもの保護のためのWebアクセス監視支援システム(L分野:ネットワークコンピューティング)
上田 達巳
,
高井 昌彰
2005
Corpus ID: 175248309
2000
2000
Impact of a new quinolone, DU-6859a, and two oral carbapenems, CS-834 and L-084, on the rat and mouse caecal microflora.
C. Liu
,
N. Kato
,
K. Watanabe
,
T. Sakata
,
T. Kaneko
Journal of Antimicrobial Chemotherapy
2000
Corpus ID: 8615388
We determined the influence of a new quinolone, DU-6859a, and two oral carbapenems, CS-834 and L-084, on the rat and mouse caecal…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE